The New Criterion: all the dope on Emerald Clinics’ limp debut

urchin-admin News

Having been long on promises but short on deliverables, the ASX listed cannabis sector is taking an evolutionary step from growing the stuff to proving that pot is indeed the healing herb it is meant to be. To date, the use of medical marijuana has been supported anecdotally but formal clinical evidence has been lacking. So it’s a race to …

The New Criterion: when high-flying tech darlings return to earth

urchin-admin News

 The savage share sell down of aerial mapper Nearmap (NEA, $1.94) highlights the dangers of investing in tech stocks valued on lusty revenue multiples that leave little room for error. Given that billion-dollar valuations have become common in the sector, no doubt other casualties will emerge as the reporting season unfolds. Nearmap shares tumbled 30 per cent after management in …

The New Criterion: stocks that tap the disaster zeitgeist

urchin-admin News

 With the stock market off to a galloping start in 2020 – at least before the coranavirus sniffles set in — most investors would have been content with a passive market exposure to the usual blue chips. As is the norm, the speculative end of the market moves to its own rhythms and influences. In this vein, here are three …